Advertisement

Cancer Immunology, Immunotherapy

, Volume 61, Issue 8, pp 1319–1325 | Cite as

Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC)

  • Suzanne Ostrand-Rosenberg
  • Pratima Sinha
  • Olesya Chornoguz
  • Christopher Ecker
Focussed Research Review

Abstract

Immune suppressive myeloid-derived suppressor cells (MDSC) are present in most cancer patients where they inhibit innate anti-tumor immunity and are a significant obstacle to cancer immunotherapy. Inflammation is a known inducer of Gr1+CD11b+ MDSC; however, the factors/conditions that regulate MDSC survival and half-life have not been identified. We have used mass spectrometry (MS) and proteomic analysis to identify proteins and pathways that regulate MDSC survival. This analysis revealed high expression of caspase family proteins and the Fas–FasL, p38 MAPK, and TGFβ pathways, suggesting that Fas–FasL apoptosis regulates MDSC survival. Flow cytometry, confocal microscopy, and western blot analyses confirmed the MS findings and demonstrated that Fas+ MDSC are susceptible to Fas-mediated killing in vitro. In vivo studies with FasL-deficient and Fas-deficient mice demonstrated that Fas–FasL interactions are essential for MDSC apoptosis and for rejection of established metastatic disease and survival and that FasL+ T cells are the effector population mediating MDSC apoptosis. MS findings validated by biological experiments demonstrated that inflammation increases MDSC levels by protecting MDSC from Fas-mediated apoptosis, possibly by activating p38 MAPK. These results demonstrate that MDSC half-life in vivo is regulated by FasL+ T cells and that inflammation increases MDSC levels by conferring resistance to Fas-mediated apoptosis and identifies T cells as the relevant effector cells causing MDSC apoptosis in vivo. This newly recognized mechanism for regulating MDSC levels identifies potential new targets for decreasing MDSC in cancer patients.

Keywords

Tumor-induced immune suppression Fas–FasL Apoptosis Inflammation PIVAC11 

Notes

Acknowledgments

We thank Dr. Robert Wiltrout for providing breeding stock of BALB/c FasL−/− and Pfp−/− mice. These studies were supported by NIH RO1CA115880 and RO1CA84232 (SOR), and American Cancer Society IRG-97-153-07 (PS). OC was supported by predoctoral fellowship W81XWH-10-10027 from the DOD CDMRP program. CE was partially supported by NIH/NIGMS MARC U*STAR T34 08663 and an HHMI Precollege and Undergraduate Science Education grant. Animal studies described herein were approved by the UMBC Institutional Animal Care and Use Committee.

Conflict of interest

The authors have no conflict of interest with the organizations sponsoring this research.

References

  1. 1.
    Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162–174PubMedCrossRefGoogle Scholar
  2. 2.
    Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867PubMedCrossRefGoogle Scholar
  3. 3.
    Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7:211–217PubMedCrossRefGoogle Scholar
  4. 4.
    Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S (2006) Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 176:284–290PubMedGoogle Scholar
  5. 5.
    Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S (2007) Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 67:10019–10026PubMedCrossRefGoogle Scholar
  6. 6.
    Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S (2007) Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 67:4507–4513PubMedCrossRefGoogle Scholar
  7. 7.
    Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G (2008) Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 181:4666–4675PubMedGoogle Scholar
  8. 8.
    Bunt SK, Clements VK, Hanson EM, Sinha P, Ostrand-Rosenberg S (2009) Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J Leukoc Biol 85:996–1004PubMedCrossRefGoogle Scholar
  9. 9.
    Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB, Gilbert J, Ochoa AC (2005) Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 202:931–939PubMedCrossRefGoogle Scholar
  10. 10.
    Song X, Krelin Y, Dvorkin T, Bjorkdahl O, Segal S, Dinarello CA, Voronov E, Apte RN (2005) CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J Immunol 175:8200–8208PubMedGoogle Scholar
  11. 11.
    Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, Ortiz M, Nacken W, Sorg C, Vogl T, Roth J, Gabrilovich DI (2008) Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 205:2235–2249PubMedCrossRefGoogle Scholar
  12. 12.
    Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W, Borrello I, Kato M, Schadendorf D, Baniyash M, Umansky V (2011) Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci USA 108:17111–17116PubMedCrossRefGoogle Scholar
  13. 13.
    Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182:4499–4506PubMedCrossRefGoogle Scholar
  14. 14.
    Perkins DN, Pappin DJ, Creasy DM, Cottrell JS (1999) Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20:3551–3567PubMedCrossRefGoogle Scholar
  15. 15.
    Chornoguz O, Grmai L, Sinha P, Artemenko KA, Zubarev RA, Ostrand-Rosenberg S (2011) Proteomic pathway analysis reveals inflammation increases myeloid-derived suppressor cell resistance to apoptosis. Mol Cell Proteomics 10:M110 002980Google Scholar
  16. 16.
    Zubarev RA, Nielsen ML, Fung EM, Savitski MM, Kel-Margoulis O, Wingender E, Kel A (2008) Identification of dominant signaling pathways from proteomics expression data. J Proteomics 71:89–96PubMedCrossRefGoogle Scholar
  17. 17.
    Sinha P, Chornoguz O, Clements VK, Artemenko KA, Zubarev RA, Ostrand-Rosenberg S (2011) Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood 117:5381–5390PubMedCrossRefGoogle Scholar
  18. 18.
    Lettau M, Paulsen M, Kabelitz D, Janssen O (2008) Storage, expression and function of Fas ligand, the key death factor of immune cells. Curr Med Chem 15:1684–1696PubMedCrossRefGoogle Scholar
  19. 19.
    Sinha P, Clements VK, Ostrand-Rosenberg S (2005) Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 174:636–645PubMedGoogle Scholar
  20. 20.
    Sinha P, Clements VK, Ostrand-Rosenberg S (2005) Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res 65:11743–11751PubMedCrossRefGoogle Scholar
  21. 21.
    Ostrand-Rosenberg S, Grusby MJ, Clements VK (2000) Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J Immunol 165:6015–6019PubMedGoogle Scholar
  22. 22.
    Yu L, Hebert MC, Zhang YE (2002) TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J 21:3749–3759PubMedCrossRefGoogle Scholar
  23. 23.
    Lin YP, Su CC, Huang JY, Lin HC, Cheng YJ, Liu MF, Yang BC (2009) Aberrant integrin activation induces p38 MAPK phosphorylation resulting in suppressed Fas-mediated apoptosis in T cells: implications for rheumatoid arthritis. Mol Immunol 46:3328–3335PubMedCrossRefGoogle Scholar
  24. 24.
    Alvarado-Kristensson M, Melander F, Leandersson K, Ronnstrand L, Wernstedt C, Andersson T (2004) p38-MAPK signals survival by phosphorylation of caspase-8 and caspase-3 in human neutrophils. J Exp Med 199:449–458PubMedCrossRefGoogle Scholar
  25. 25.
    Xu G, Shi Y (2007) Apoptosis signaling pathways and lymphocyte homeostasis. Cell Res 17:759–771PubMedCrossRefGoogle Scholar
  26. 26.
    Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166:678–689PubMedGoogle Scholar
  27. 27.
    Young MR, Petruzzelli GJ, Kolesiak K, Achille N, Lathers DM, Gabrilovich DI (2001) Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34(+) progenitor cells. Hum Immunol 62:332–341PubMedCrossRefGoogle Scholar
  28. 28.
    Makarenkova VP, Bansal V, Matta BM, Perez LA, Ochoa JB (2006) CD11b +/Gr-1 + myeloid suppressor cells cause T cell dysfunction after traumatic stress. J Immunol 176:2085–2094PubMedGoogle Scholar
  29. 29.
    Van Ginderachter JA, Beschin A, De Baetselier P, Raes G (2010) Myeloid-derived suppressor cells in parasitic infections. Eur J Immunol 40:2976–2985PubMedCrossRefGoogle Scholar
  30. 30.
    Grizzle WE, Xu X, Zhang S, Stockard CR, Liu C, Yu S, Wang J, Mountz JD, Zhang HG (2007) Age-related increase of tumor susceptibility is associated with myeloid-derived suppressor cell mediated suppression of T cell cytotoxicity in recombinant inbred BXD12 mice. Mech Ageing Dev 128:672–680PubMedCrossRefGoogle Scholar
  31. 31.
    Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S (2009) Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+T cells. J Immunol 183:937–944PubMedCrossRefGoogle Scholar
  32. 32.
    Zhu B, Bando Y, Xiao S, Yang K, Anderson AC, Kuchroo VK, Khoury SJ (2007) CD11b + Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol 179:5228–5237PubMedGoogle Scholar
  33. 33.
    Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545PubMedCrossRefGoogle Scholar
  34. 34.
    Johansson M, Denardo DG, Coussens LM (2008) Polarized immune responses differentially regulate cancer development. Immunol Rev 222:145–154PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Suzanne Ostrand-Rosenberg
    • 1
  • Pratima Sinha
    • 1
  • Olesya Chornoguz
    • 1
  • Christopher Ecker
    • 1
  1. 1.Department of Biological SciencesUniversity of Maryland Baltimore CountyBaltimoreUSA

Personalised recommendations